Recent evidence has shown that miR-221 is elevated within lung samples and isolated pulmonary artery VSMCs from PAH patients and animal models of PAH, and miR-221 directly targets a negative regulator of the β-catenin signalling pathway AXIN2, to promote VSMC proliferation [145]. The gene discussed is AXIN2; the disease is pulmonary arterial hypertension.